Humacyte Inc · Q4 2022 earnings

Briefing

Humacyte reported financial results for the fourth quarter and year ended December 31, 2022, and highlighted recent corporate accomplishments.

Humacyte reported no revenue for Q4 2022, research and development expenses of $15.0 million, general and administrative expenses of $5.8 million, and a net loss of $3.7 million. The company's cash, cash equivalents, and short-term investments totaled $151.9 million as of December 31, 2022.

• Enrollment nearing completion in Phase 2/3 V005 trial in vascular trauma with 63 patients having received the HAV.
• 17 vascular trauma patients have been treated with the HAV under the humanitarian program in Ukraine.
• Enrollment nearing completion in Phase 3 V007 trial in arteriovenous (AV) access with 238 patients enrolled.
• Six-year results from the Phase 2 trial of the HAV in peripheral artery disease (PAD) were published in Journal of Vascular Surgery – Vascular Science.

Headline financials

Revenue & EPS history

Humacyte believes that its cash, cash equivalents and short-term investments are adequate to fund operations through the end of 2024, past the Company’s current expected timelines for potential approval of the HAV in its vascular trauma indication.